Stephen C. Glover

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Weston, FL
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Kirk Look, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Stephen C. Glover

Form 4 holding Director

Ambrx Biopharma Inc.

Security class
Ordinary Shares
Shares / value
85,000
Estimated value
$785,800
Report date
07 Jun 2023
Price
$9.24
Ownership
Direct
Form 4 holding Director

PDS Biotechnology Corp

Security class
Common Stock
Shares / value
78,851
Estimated value
$130,893
Report date
28 Feb 2025
Price
$1.66
Ownership
Direct
Form 4 holding Director

Ambrx Biopharma, Inc.

Security class
Restricted Stock Units
Shares / value
0
Estimated value
$0
Report date
07 Mar 2024
Price
$9.82
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

PDS Biotechnology Corp

Security class
Employee Stock Option (Right to Buy)
Shares / value
54,876
Estimated value
Report date
12 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Ambrx Biopharma Inc.

Security class
Stock Option (right to buy)
Shares / value
17,500
Estimated value
Report date
18 May 2023
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

PDS Biotechnology Corp

Security class
Common Warrant
Shares / value
15,061
Estimated value
Report date
28 Feb 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

ZyVersa Therapeutics, Inc.

Security class
Stock Options
Shares / value
1,627
Estimated value
Report date
24 May 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Ambrx Biopharma, Inc.

Security class
Option to Purchase Common Stock
Shares / value
0
Estimated value
Report date
07 Mar 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Stephen C. Glover

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .